CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
13 janv. 2025 07h00 HE
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet by $11.25M in Unrestricted Cash through Oversubscribed Shareholder Rights Offering and Satisfied Debt Covenant
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
06 janv. 2025 07h00 HE
|
CytoSorbents
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai, United Arab Emirates, a Gateway to the Middle East and Africa
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
03 janv. 2025 07h00 HE
|
CytoSorbents
CytoSorbents' Preliminary Unaudited Q4 2024 Product Revenue Increased 22-25% From A Year Ago With Product Gross Margins Of ~70%
CytoSorbents Rights Offering Begins
23 déc. 2024 07h00 HE
|
CytoSorbents
CytoSorbents Rights Offering Begins. Eligible Stockholders are Being Distributed a Dividend of Subscription Rights Based on Shares of CTSO Held.
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
12 déc. 2024 07h00 HE
|
CytoSorbents
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
CytoSorbents Announces Rights Offering
09 déc. 2024 07h00 HE
|
CytoSorbents
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
26 nov. 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Participate in the Piper Sandler 36th Annual Healthcare Conference. Management holding one-on-one meetings with investors
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
11 nov. 2024 07h30 HE
|
CytoSorbents; Converge Biotech
CytoSorbents and Converge Biotech Partner In India to Expand CytoSorb Blood Purification Availability to Treat Sepsis and Other Deadly Conditions
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07 nov. 2024 16h05 HE
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22 oct. 2024 07h00 HE
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected